Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.
Category: drug costs
Podcast: KHN’s ‘What The Health?’ Reading The Tea Leaves In Blue Wave’s Wake
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHN’s Jay Hancock about the latest “Bill of the Month.”
Podcast: KHN’s ‘What The Health?’ Doctors, Guns And Lame Ducks
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Kimberly Leonard of the Washington Examiner and Alice Ollstein of Politico discuss how the Democrats’ takeover of the House and other results from the Nov. 6 elections might affect health care, and what Congress may have in store for the lame-duck session.
Podcast: KHN’s ‘What The Health?’ Open Enrollment And A Midterm Preview
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Joanne Kenen of Politico discuss the start of open enrollment for individual health insurance plans for 2019 and preview what next week’s midterm elections might mean for health policy. Plus, Barbara Feder Ostrov of KHN and California Healthline talks to Julie about the latest NPR-KHN “Bill of the Month” feature.